SCHEMBL5202901

SCHEMBL5202901

c1ccc2c(-n3cccc3)nccc2c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
COMT P21964 1/20 0.58
HRH4 Q9H3N8 1/20 0.53
HTR2C P28335 1/20 0.53
PLAU P00749 2/20 0.48
CYP2A6 P11509 1/20 0.48
F12 P00748 1/20 0.48
NCF1 P14598 1/20 0.48
NOS3 P29474 1/20 0.48
NOS1 P29475 1/20 0.48
NOS2 P35228 1/20 0.48
BACE1 P56817 1/20 0.48
SORD Q00796 2/20 0.43
MAPT P10636 2/20 0.43
NPC1 O15118 2/20 0.43
ALDH1A1 P00352 1/20 0.43
RAB9A P51151 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
PLG P00747 1/20 0.41
LMNA P02545 2/20 0.40
CFTR P13569 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7646271 0.82 COMT (0.52) COMTHRH4HTR2CPLAUCYP2A6
SCHEMBL31556369 0.76 MAPK1 (0.59) COMTHRH4HTR2CPLAUCYP2A6
SCHEMBL6082267 0.74 COMT (0.63) COMTHRH4HTR2CSORDMAPT
SCHEMBL1264765 0.74 POLB (0.54) COMTHRH4HTR2CPLAUCYP2A6
SCHEMBL29003692 0.73 HRH4 (0.73) HRH4HTR2CSORDMAPTALDH1A1
SCHEMBL30275021 0.73 HRH4 (0.73) HRH4HTR2CSORDMAPTALDH1A1
SCHEMBL15824969 0.73 HRH4 (0.46) COMTHRH4HTR2CPLAUCYP2A6
SCHEMBL4065670 0.72 CDC7 (0.51) COMTHRH4HTR2CPLAUCYP2A6
SCHEMBL4766806 0.72 HRH4 (0.71) HRH4HTR2CSORDMAPTALDH1A1
SCHEMBL3749098 0.71 COMT (0.49) COMTHRH4HTR2CPLAUCYP2A6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115974876-B Method for preparing fullerene pyrrolidine isoquinoline based on participation of o-phenylacetylene benzaldehyde 湖北大学 2025-05-23 CN disclosed
EP-1351950-B1 ISOQUINOLINYL AROYL PYRROLE COMPOUNDS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS ORTHO MCNEIL PHARM INC (US) 2007-08-08 EP disclosed
EP-1351950-A2 ISOINDOLYL AND ISOQUINOLINYL AROYL PYRROLE COMPOUNDS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS Ortho-McNeil Pharmaceutical, Inc. (US) 2003-10-15 EP disclosed
US-6492387-B2 ADMINISTERED AS AN ANTICONVULSANT AGENT, ANTIEPILEPTIC AGENT, NEUROPROTECTIVE AGENT, MUSCLE RELAXANT AGENT AND AGENT FOR THE TREATMENT OF NEUROPATHIC PAIN. ORTHO-MCNEIL PHARAMACEUTICAL, INC. 2002-12-10 US disclosed
US-20020128286-A1 Isoindolyl and isoquinolinyl aroyl pyrrole compounds ORTHO-MCNEIL PHARMACEUTICAL, INC. 2002-09-12 US disclosed
WO-2002057253-A2 ISOINDOLYL AND ISOQUINOLINYL AROYL PYRROLE COMPOUNDS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2002-07-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020128286-A1 Isoindolyl and isoquinolinyl aroyl pyrrole compounds QPCT, INA, OPRK1 COMT 14/4885HRH4 510/4885HTR2C 225/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.